Identification of biomarkers of immune checkpoint blockade efficacy in recurrent or refractory solid tumor malignancies

Patients with advanced solid malignancies recurrent or resistant to standard therapy have limited treatment options. The role of molecular biomarkers for predicting immune checkpoint blockade (ICB) efficacy are not well characterized in these patients. Tumor mutational profiles of 490 patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Richard K., Qing, Yun, Jelloul, Fatima Zahra, Routbort, Mark J., Wang, Peng, Shaw, Kenna, Zhang, Jiexin, Lee, Jack, Medeiros, L. Jeffrey, Kopetz, Scott, Tetzlaff, Michael T., Broaddus, Russell R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7021232/
https://www.ncbi.nlm.nih.gov/pubmed/32110280
http://dx.doi.org/10.18632/oncotarget.27466

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7021232/
https://www.ncbi.nlm.nih.gov/pubmed/32110280
http://dx.doi.org/10.18632/oncotarget.27466

Ejemplares similares